Skip to main content

PerkinElmer Completes $600M Acquisition of Caliper

Premium

PerkinElmer said this week that it has completed its acquisition of Caliper Life Sciences for around $600 million.

The agreement, which was announced in September, will, among other things, allow PerkinElmer to combine its expertise in informatics with Caliper's automation and sample-prep technology to bolster PerkinElmer's presence in the next-generation sequencing space (IS 9/13/2011).

In a statement, PerkinElmer CEO Robert Friel said that the deal will "strengthen PerkinElmer's position in personalized medicine."

As part of the deal, Caliper CEO Kevin Hrusovsky will join PerkinElmer as president of life sciences and technology to lead a newly created $500 million business that integrates Caliper with PerkinElmer's research business. Hrusovsky said the business will give "customers the tools and insights" to "understand the origins of disease, create new therapies, and transform personalized medicine."

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.